The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:2424-2426 June 7, 2007 Number 23
NextNext

Amiodarone for Atrial Fibrillation

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Zimetbaum, P.
-PubMed Citation
To the Editor: In his review article on amiodarone for atrial fibrillation, Zimetbaum (March 1 issue)1 did not mention that there are two forms of amiodarone-induced thyrotoxicosis (AIT) — an important distinction that has a major influence on subsequent management. In type I AIT, patients usually have preexisting thyroid abnormalities, such as nodular goiter, an autonomous thyroid nodule, or latent Graves' disease. This syndrome is thought to be due to the Jod–Basedow phenomenon. In type II AIT, the thyroid gland is normal, and thyrotoxicosis results from subacute destructive thyroiditis with the release of preformed thyroid hormone. The uptake of radioactive . . . [Full Text of this Article]


This article has been cited by other articles:


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.